Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis

Park, Se Hee; Nam, Joo Young; Han, Eugene; Lee, Yong-Ho; Lee, Byung Wan; Kim, Beom Seok; Soo, Bong; Kim, Chul Sik; Kang, Eun Seok

doi:10.1097/md.0000000000004543

Cited by 14 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While there were no significant differences in the relationship between acute glucose lowering and plasma DPP‐4 inhibition for the DPP‐4 inhibitors investigated in our study, the methods used were not designed to rule out potentially small differences between these agents. The observation that different DPP4 inhibitors have similar glucose‐lowering efficacy in the clinic has been reported in the literature (eg, Park et al) although there is a paucity of directly comparative studies. Moreover, despite the fact that soluble DPP‐4 in mixed venous plasma comprises only a small part of the total pool of DPP‐4 in the body, the majority being membrane bound, the extent of inhibition of the plasma enzyme does appear to predict glucose‐lowering activity well in mice as well as in humans …”

Section: Discussionmentioning

confidence: 84%

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

Berger

SinhaRoy

Pocai

et al. 2017

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Results: Firstly, using a combination of published crystal structures and in-house data, we demonstrated that the binding site utilized by all of the DPP-4 inhibitors assessed was the same as that used by neuropeptide Y, supporting the hypothesis that DPP-4 inhibitors are able to competitively inhibit endogenous substrates for the enzyme.Secondly, we ascertained that the enzymatic cleft of DPP-4 is a relatively large cavity which displays conformational flexibility to accommodate structurally diverse inhibitor molecules. Finally, we found that for all inhibitors, irrespective of their chemical structure, the inhibition of plasma DPP-4 enzyme activity correlates directly with acute plasma glucose lowering in mice. Conclusion:The common binding site utilized by different DPP-4 inhibitors enables similar competitive inhibition of the cleavage of the endogenous DPP-4 substrates.Furthermore, despite chemical diversity and a range of binding potencies observed amongst the DPP-4 inhibitors, a direct relationship between enzyme inhibition in the plasma and glucose lowering is evident in mice for each member of the classes studied.

show abstract

Section: Discussionmentioning

confidence: 84%

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

Berger

SinhaRoy

Pocai

et al. 2017

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

show abstract

“…These drugs, which were approved for clinical use in 2006, provide an effective therapeutic option without the drawback of inducing hypoglycemia and can be used safely in patients receiving dialysis. DPP-4 inhibitor use was found to significantly improve the HbA1c level and hyperglycemia in patients receiving PD [33,34]. Glycemic control is known to influence clinical outcomes, including mortality, in patients with chronic kidney disease who are and are not receiving dialysis.…”

Section: Discussionmentioning

confidence: 99%

Comparison of peritoneal dialysis and hemodialysis as first renal replacement therapy in patients with end-stage renal disease and diabetes: a systematic review

Maruyama

Higuchi

et al. 2019

Ren Replace Ther

View full text Add to dashboard Cite

Background: Diabetes has become the most common cause of end-stage renal disease (ESRD) requiring renal replacement therapy (RRT) in most countries around the world. Peritoneal dialysis (PD) is valuable for patients newly requiring RRT because of the preservation of residual renal function (RRF), higher quality of life, and hemodynamic stability in comparison with hemodialysis (HD). A previous systematic review produced conflicting results regarding patient survival. As several advances have been made in therapy for diabetic patients receiving PD, we conducted a systematic review of studies published after 2014 to determine whether incident PD or HD is advantageous for the survival of patients with diabetes. Methods: For this systematic review, the MEDLINE, EMBASE, and CENTRAL databases were searched to identify articles published between February 2014 and August 2017. The quality of studies was assessed using the GRADE approach. Outcomes of interest were all-cause mortality; RRF; major morbid events, including cardiovascular disease (CVD) and infectious disease; and glycemic control. This review was performed using a predefined protocol published in PROSPERO (CRD42018104258). Results: Sixteen studies were included in this review. All were retrospective observational studies, and the risk of bias, especially failure to adequately control confounding factors, was high. Among them, 15 studies investigated allcause mortality in diabetic patients initiating PD and HD. Differences favoring HD were observed in nine studies, whereas those favoring PD were observed in two studies. Two studies investigated effects on CVD, and both demonstrated the superiority of incident HD. No study investigated the effect of any other outcome. Conclusions: In the present systematic review, the risk of death tended to be higher among diabetic patients with ESRD newly initiating RRT with incident PD in comparison with incident HD. However, we could not obtain definitive results reflecting the superiority of PD or HD with regard to patient outcomes because of the severe risk of bias and the heterogeneity of management strategies for diabetic patients receiving dialysis. Further studies are needed to clarify the advantages of PD and HD as RRT for diabetic patients with ESRD.

show abstract

“…The results of DPP-4 inhibitors' effects on lipid metabolism parameters are diverse and inconclusive [2]. Park et al reported a significant increase in HDL concentration in patients with 12-week administration of sitagliptin or linagliptin, and showed a decreasing trend in TC, TG, and LD in patients with 12-week administration of sitagliptin, vildagliptin, or linagliptin [19]. Kubota et al reported that administration of sitagliptin significantly decreased TC and LDL concentrations, and tended to decrease HDL concentration in patients with type 2 DM, up to 12 weeks [9].…”

Section: Discussionmentioning

confidence: 99%

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus

Nishida

Takahashi

Tezuka

et al. 2020

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

Background: The purpose of this study was to evaluate and compare the effects on laboratory parameters among monotherapy with five DPP-4 inhibitors in patients with type 2 diabetes mellitus (DM). Methods: We identified cohorts of new sitagliptin users (n = 879), vildagliptin users (n = 253), teneligliptin users (n = 260), alogliptin users (n = 237), and linagliptin users (n = 180) in patients with type 2 DM. We used a multivariate regression model to evaluate and compare the effects of the drugs on laboratory parameters including HbA1c concentration and serum concentrations of creatinine, estimated glomerular filtration rate, high density lipoprotein, total cholesterol, triglyceride, aspartate aminotransferase, and alanine aminotransferase among the five DPP-4 inhibitors up to 12 months. Results: Our study showed a favorable effect on HbA1c concentration and a slightly unfavorable effect on serum creatinine concentration in users of the five DPP-4 inhibitors, a favorable effect on lipid metabolism in sitagliptin, vildagliptin, and alogliptin users, and a favorable effect on hepatic parameters in sitagliptin, alogliptin, and linagliptin users, in comparison of the baseline and exposure periods. However, there was no significant difference in mean change in the concentration of any laboratory parameter among the five groups of DPP-4 inhibitor users. Conclusions: In this study, we showed the effect of five DPP-4 inhibitors on glycemic, renal, and lipid metabolism, and hepatic parameters. DPP-4 inhibitors are well-tolerated hypoglycemic drugs.

show abstract

Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis

Abstract: Supplemental Digital Content is available in the text

Cited by 14 publications

References 30 publications

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

Comparison of peritoneal dialysis and hemodialysis as first renal replacement therapy in patients with end-stage renal disease and diabetes: a systematic review

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus

Contact Info

Product

Resources

About